{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:47:32Z","timestamp":1791906452451,"version":"4.3.4"},"reference-count":258,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Treating neurological disorders in children is particularly challenging due to the dynamic maturation of the developing brain, age-dependent pharmacokinetics, and evolving structural and functional properties of the blood\u2013brain barrier (BBB). This review explores the latest advances in drug-delivery systems tailored for pediatric neurology, emphasizing strategies to address physiological and developmental determinants of treatment response across infancy, childhood, and adolescence. The paper begins by outlining the distinct challenges of drug delivery in children, focusing on BBB maturation, transporter expression, metabolic capacity, and neurodevelopmental vulnerability. Emerging delivery systems, such as liposomes, polymeric nanoparticles, dendrimers, micelles, gold nanoparticles, and gene- and RNA-based vectors, are further reviewed in relation to major pediatric neurological conditions. These platforms demonstrate promise in enhancing drug bioavailability, targeting specific brain regions, and minimizing systemic toxicity. This paper also covers important safety, regulatory, and ethical considerations in pediatric populations, with a focus on the need for age-appropriate design and thorough clinical validation. Concluding with emerging trends and future directions, this work serves as a comprehensive resource for advancing pediatric neurological therapeutics through state-of-the-art drug delivery technologies.<\/jats:p>","DOI":"10.3390\/ijms27198727","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:33:12Z","timestamp":1790699592000},"page":"8727","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advanced Drug Delivery in Pediatric Neurology: Developmental Barriers, Nanocarrier Strategies, and Translational Challenges"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3038-6939","authenticated-orcid":false,"given":"Raluca Ioana","family":"Teleanu","sequence":"first","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea Gabriela","family":"Bratu","sequence":"additional","affiliation":[{"name":"Faculty of Chemical Engineering and Biotechnologies, National University of Science and Technology POLITEHNICA Bucharest, 011061 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8968-504X","authenticated-orcid":false,"given":"Adelina-Gabriela","family":"Niculescu","sequence":"additional","affiliation":[{"name":"Faculty of Chemical Engineering and Biotechnologies, National University of Science and Technology POLITEHNICA Bucharest, 011061 Bucharest, Romania"},{"name":"Research Institute of the University of Bucharest\u2014ICUB, University of Bucharest, 050657 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7014-7065","authenticated-orcid":false,"given":"Radu \u0218tefan","family":"Perjoc","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5061-7821","authenticated-orcid":false,"given":"Eugenia","family":"Roza","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Mihai","family":"Teleanu","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana Aurelia","family":"Vlad\u00e2cenco","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Cojocaru","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3036-094X","authenticated-orcid":false,"given":"Alexandru Mihai","family":"Grumezescu","sequence":"additional","affiliation":[{"name":"Faculty of Chemical Engineering and Biotechnologies, National University of Science and Technology POLITEHNICA Bucharest, 011061 Bucharest, Romania"},{"name":"Research Institute of the University of Bucharest\u2014ICUB, University of Bucharest, 050657 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iustina Mihaela","family":"Pintilie","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1227\/neu.0000000000001976","article-title":"Letter: The World Health Organization\u2019s Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders 2022\u20132031","volume":"90","author":"Kanmounye","year":"2022","journal-title":"Neurosurgery"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100692","DOI":"10.1016\/j.medj.2025.100692","article-title":"Burden of neurological disorders in China and its provinces, 1990\u20132021: Findings from the global burden of disease study 2021","volume":"6","author":"Zhang","year":"2025","journal-title":"Med"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.spen.2018.03.002","article-title":"Global Burden of Pediatric Neurological Disorders","volume":"27","author":"Newton","year":"2018","journal-title":"Semin. Pediatr. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Domingues, C., Jarak, I., Veiga, F., Dourado, M., and Figueiras, A. (2023). Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15102431"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.33263\/BRIAC146.145","article-title":"A Comprehensive Review of Pediatric Drug Development: An Extensive Analysis of Present Difficulties and Prospects for the Future","volume":"14","author":"Chandramouli","year":"2024","journal-title":"Biointerface Res. Appl. Chem."},{"key":"ref_6","first-page":"24","article-title":"Advancements and challenges in pediatric pharmacotherapy: A comprehensive review","volume":"3","author":"Khan","year":"2025","journal-title":"Glob. J. Health Sci. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/2168479018812060","article-title":"The Meanings of \u201cPediatric Drug Development\u201d","volume":"53","author":"Rose","year":"2019","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e2112760","DOI":"10.1001\/jamanetworkopen.2021.12760","article-title":"The Scarcity of Approved Pediatric High-Risk Medical Devices","volume":"4","author":"Espinoza","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/08830738211037470","article-title":"US Food and Drug Administration Facilitated Pediatric Approval Programs: Application to Pediatric Neurological Disorders","volume":"37","author":"Cruz","year":"2022","journal-title":"J. Child Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Haigo, H., Matsuda, K., and Shikano, M. (2025). Clinical data required for the approval of pediatric pharmaceuticals in Japan. BMC Pediatr., 25.","DOI":"10.1186\/s12887-025-05646-0"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1002\/wdev.363","article-title":"Postnatal development of cerebrovascular structure and the neurogliovascular unit","volume":"9","author":"Shih","year":"2020","journal-title":"Wiley Interdiscip. Rev. Dev. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00429-022-02592-w","article-title":"In mice and humans, brain microvascular contractility matures postnatally","volume":"228","author":"Slaoui","year":"2023","journal-title":"Brain Struct. Funct."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1136\/neurintsurg-2021-018607","article-title":"Cerebral neurovascular embryology, anatomic variations, and congenital brain arteriovenous lesions","volume":"14","author":"Klostranec","year":"2022","journal-title":"J. NeuroInterventional Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood\u2013brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"a020412","DOI":"10.1101\/cshperspect.a020412","article-title":"The blood-brain barrier","volume":"7","author":"Daneman","year":"2015","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/B978-0-12-804279-3.00002-2","article-title":"Chapter 2\u2014The cerebrospinal fluid and barriers\u2014anatomic and physiologic considerations","volume":"Volume 146","author":"Deisenhammer","year":"2018","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/nm.3407","article-title":"Development, maintenance and disruption of the blood-brain barrier","volume":"19","author":"Obermeier","year":"2013","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"114303","DOI":"10.1016\/j.addr.2022.114303","article-title":"Drug delivery across the blood-brain barrier for the treatment of pediatric brain tumors\u2014An update","volume":"185","author":"Power","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.reprotox.2017.06.043","article-title":"The great barrier belief: The blood\u2013brain barrier and considerations for juvenile toxicity studies","volume":"72","author":"Schmitt","year":"2017","journal-title":"Reprod. Toxicol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Gao, Q., Song, D., Xu, D., Chai, X., and Ge, M. (2025). Characteristics of the blood\u2013brain barrier in pediatric brain tumors. Front. Pediatr., 13.","DOI":"10.3389\/fped.2025.1646641"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1208\/s12249-025-03198-1","article-title":"Advancements in Liposomal Drug Delivery Systems for Paediatric Neurological Disorders: A Comprehensive Review","volume":"26","author":"Hari","year":"2025","journal-title":"AAPS PharmSciTech"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ccell.2016.03.002","article-title":"Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype","volume":"29","author":"Phoenix","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s13311-017-0526-y","article-title":"Medulloblastoma: Molecular Classification-Based Personal Therapeutics","volume":"14","author":"Archer","year":"2017","journal-title":"Neurotherapeutics"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","author":"Fang","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2147\/IJN.S61288","article-title":"Current approaches to enhance CNS delivery of drugs across the brain barriers","volume":"9","author":"Lu","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s40263-020-00766-w","article-title":"Overview of Current Drug Delivery Methods Across the Blood\u2013Brain Barrier for the Treatment of Primary Brain Tumors","volume":"34","author":"Haumann","year":"2020","journal-title":"CNS Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/cpt.18","article-title":"Targeted delivery of protein and gene medicines through the blood-brain barrier","volume":"97","author":"Pardridge","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11940-020-00651-3","article-title":"Advances in Targeted Therapies for Pediatric Brain Tumors","volume":"22","author":"Mueller","year":"2020","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pediatrneurol.2021.09.011","article-title":"Gene-Targeted Therapies in Pediatric Neurology: Challenges and Opportunities in Diagnosis and Delivery","volume":"125","author":"Shellhaas","year":"2021","journal-title":"Pediatr. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature13165","article-title":"Capillary pericytes regulate cerebral blood flow in health and disease","volume":"508","author":"Hall","year":"2014","journal-title":"Nature"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41586-020-2589-x","article-title":"Interpericyte tunnelling nanotubes regulate neurovascular coupling","volume":"585","author":"Quintero","year":"2020","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"7253","DOI":"10.1021\/acs.jmedchem.2c01824","article-title":"Explaining Blood\u2013Brain Barrier Permeability of Small Molecules by Integrated Analysis of Different Transport Mechanisms","volume":"66","author":"Cornelissen","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11065-010-9148-4","article-title":"The Basics of Brain Development","volume":"20","author":"Stiles","year":"2010","journal-title":"Neuropsychol. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Budday, S., Steinmann, P., and Kuhl, E. (2015). Physical biology of human brain development. Front. Cell. Neurosci., 9.","DOI":"10.3389\/fncel.2015.00257"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00401-018-1809-z","article-title":"The meninges as barriers and facilitators for the movement of fluid, cells and pathogens related to the rodent and human CNS","volume":"135","author":"Weller","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1203\/01.PDR.0000180535.14093.FB","article-title":"Development of Tight Junction Molecules in Blood Vessels of Germinal Matrix, Cerebral Cortex, and White Matter","volume":"58","author":"Ballabh","year":"2005","journal-title":"Pediatr. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.placenta.2016.12.005","article-title":"Review: The blood-brain barrier; protecting the developing fetal brain","volume":"54","author":"Miller","year":"2017","journal-title":"Placenta"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2003.12.016","article-title":"The blood-brain barrier: An overview: Structure, regulation, and clinical implications","volume":"16","author":"Ballabh","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/pr.2015.119","article-title":"The ontogeny of P-glycoprotein in the developing human blood-brain barrier: Implication for opioid toxicity in neonates","volume":"78","author":"Lam","year":"2015","journal-title":"Pediatr. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1023\/A:1016581801188","article-title":"Immunogold study of interendothelial junction-associated and glucose transporter proteins during postnatal maturation of the mouse blood-brain barrier","volume":"30","author":"Vorbrodt","year":"2001","journal-title":"J. Neurocytol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00441-014-1811-2","article-title":"Novel insights into the development and maintenance of the blood\u2013brain barrier","volume":"355","author":"Engelhardt","year":"2014","journal-title":"Cell Tissue Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1113\/JP275376","article-title":"Physiology and molecular biology of barrier mechanisms in the fetal and neonatal brain","volume":"596","author":"Saunders","year":"2018","journal-title":"J. Physiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nrn3114","article-title":"Neurovascular pathways to neurodegeneration in Alzheimer\u2019s disease and other disorders","volume":"12","author":"Zlokovic","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.neuron.2017.03.043","article-title":"Blood-Brain Barrier Permeability Is Regulated by Lipid Transport-Dependent Suppression of Caveolae-Mediated Transcytosis","volume":"94","author":"Andreone","year":"2017","journal-title":"Neuron"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40478-017-0470-4","article-title":"Transmission of \u03b1-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: Another mechanism for initiation and progression of Parkinson\u2019s disease?","volume":"5","author":"Matsumoto","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1161\/ATVBAHA.107.161521","article-title":"Endothelial-Mural Cell Signaling in Vascular Development and Angiogenesis","volume":"29","author":"Gaengel","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature09522","article-title":"Pericytes regulate the blood\u2013brain barrier","volume":"468","author":"Armulik","year":"2010","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1038\/s41598-023-29894-1","article-title":"The tight junction protein occludin modulates blood\u2013brain barrier integrity and neurological function after ischemic stroke in mice","volume":"13","author":"Sugiyama","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1111\/febs.13412","article-title":"The dynamic blood\u2013brain barrier","volume":"282","author":"Keaney","year":"2015","journal-title":"FEBS J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1248\/bpb.b21-00408","article-title":"Claudin-5: A Pharmacological Target to Modify the Permeability of the Blood\u2013Brain Barrier","volume":"44","author":"Hashimoto","year":"2021","journal-title":"Biol. Pharm. Bull."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4103\/bc.bc_29_20","article-title":"Occludin regulation of blood-brain barrier and potential therapeutic target in ischemic stroke","volume":"6","author":"Yuan","year":"2020","journal-title":"Brain Circ."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"110656","DOI":"10.1016\/j.celrep.2022.110656","article-title":"An oxygen-adaptive interaction between SNHG12 and occludin maintains blood-brain barrier integrity","volume":"39","author":"Li","year":"2022","journal-title":"Cell Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","article-title":"A blood\u2013brain barrier overview on structure, function, impairment, and biomarkers of integrity","volume":"17","author":"Kadry","year":"2020","journal-title":"Fluids Barriers CNS"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.3892\/etm.2016.3557","article-title":"Plasmalemma vesicle-associated protein: A crucial component of vascular homeostasis","volume":"12","author":"Guo","year":"2016","journal-title":"Exp. Ther. Med."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Shue, E.H., Carson-Walter, E.B., Liu, Y., Winans, B.N., Ali, Z.S., Chen, J., and Walter, K.A. (2008). Plasmalemmal Vesicle Associated Protein-1 (PV-1) is a marker of blood-brain barrier disruption in rodent models. BMC Neurosci., 9.","DOI":"10.1186\/1471-2202-9-29"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/cvr\/cvv216","article-title":"Endothelial G\u03b1q\/11 is required for VEGF-induced vascular permeability and angiogenesis","volume":"108","author":"Sivaraj","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/ar.22878","article-title":"VEGF Increases Paracellular Permeability in Brain Endothelial Cells via Upregulation of EphA2","volume":"297","author":"Miao","year":"2014","journal-title":"Anat. Rec."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/jdn.10027","article-title":"Neonatal excitotoxicity modifies blood-brain barrier properties increasing its susceptibility to hypertonic shock in adulthood","volume":"80","year":"2020","journal-title":"Int. J. Dev. Neurosci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/nen.0b013e31815f65d9","article-title":"Fetal blood-brain barrier P-glycoprotein contributes to brain protection during human development","volume":"67","author":"Virgintino","year":"2008","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00418-020-01884-8","article-title":"Developmental patterns in human blood-brain barrier and blood-cerebrospinal fluid barrier ABC drug transporter expression","volume":"154","author":"Verscheijden","year":"2020","journal-title":"Histochem. Cell Biol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Lye, P., Bloise, E., Imperio, G.E., Chitayat, D., and Matthews, S.G. (2022). Functional Expression of Multidrug-Resistance (MDR) Transporters in Developing Human Fetal Brain Endothelial Cells. Cells, 11.","DOI":"10.3390\/cells11142259"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.2174\/138161211797440186","article-title":"Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up","volume":"17","author":"Agarwal","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Sch\u00e4fer, A.M., Meyer Zu Schwabedissen, H.E., and Grube, M. (2021). Expression and Function of Organic Anion Transporting Polypeptides in the Human Brain: Physiological and Pharmacological Implications. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13060834"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2174\/138920011798357051","article-title":"Blood-Brain Barrier P450 Enzymes and Multidrug Transporters in Drug Resistance: A Synergistic Role in Neurological Diseases","volume":"12","author":"Ghosh","year":"2011","journal-title":"Curr. Drug Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/j.1528-1167.2009.02428.x","article-title":"Pattern of P450 expression at the human blood-brain barrier: Roles of epileptic condition and laminar flow","volume":"51","author":"Ghosh","year":"2010","journal-title":"Epilepsia"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"340","DOI":"10.5937\/arhfarm72-37605","article-title":"Pediatric pharmacokinetic considerations and implications for drug dosing","volume":"72","year":"2022","journal-title":"Arh. ZA Farm."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40262-014-0134-5","article-title":"Dosing in Children: A Critical Review of the Pharmacokinetic Allometric Scaling and Modelling Approaches in Paediatric Drug Development and Clinical Settings","volume":"53","author":"Mahmood","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1177\/2168479019856572","article-title":"Pediatric Age Groups and Approach to Studies","volume":"53","author":"Job","year":"2019","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bcp.12267","article-title":"Paediatric pharmacokinetics: Key considerations","volume":"79","author":"Batchelor","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_71","first-page":"S10","article-title":"Developmental Changes in Pharmacokinetics and Pharmacodynamics","volume":"58","author":"Reed","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology--drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2165\/00003088-200645110-00003","article-title":"Guidelines on Paediatric Dosing on the Basis of Developmental Physiology and Pharmacokinetic Considerations","volume":"45","author":"Bartelink","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejpn.2009.09.005","article-title":"The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy","volume":"14","author":"Heinen","year":"2010","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0883073815627882","article-title":"Intrathecal Injections in Children with Spinal Muscular Atrophy","volume":"31","author":"Swoboda","year":"2016","journal-title":"J. Child. Neurol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Schreiner, T.G., Men\u00e9ndez-Gonz\u00e1lez, M., Schreiner, O.D., and Ciobanu, R.C. (2025). Intrathecal Therapies for Neurodegenerative Diseases: A Review of Current Approaches and the Urgent Need for Advanced Delivery Systems. Biomedicines, 13.","DOI":"10.3390\/biomedicines13092167"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3324\/haematol.2020.268565","article-title":"Methotrexate-related central neurotoxicity: Clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia","volume":"107","author":"Mateos","year":"2021","journal-title":"Haematologica"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11060-023-04388-2","article-title":"Efficacy of intrathecal methotrexate in children with high-risk medulloblastoma over three years: A retrospective study from a single center","volume":"164","author":"Zhang","year":"2023","journal-title":"J. Neuro-Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pediatrneurol.2026.01.002","article-title":"Intrathecal Baclofen Therapy in Children: Testing, Dose-Finding, and Complications\u2014A Single-Center Experience","volume":"177","author":"Held","year":"2026","journal-title":"Pediatr. Neurol."},{"key":"ref_80","first-page":"Cd004552","article-title":"Intrathecal baclofen for treating spasticity in children with cerebral palsy","volume":"2015","author":"Hasnat","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Bekta\u015f, \u00d6., G\u00fcl\u015fen, M., Dursun, O.B., Tekin, A., Y\u00fcksel, D., Demir, E., \u00d6zt\u00fcrk, G., Salt\u0131k, S., Herg\u00fcler, \u00d6., and \u00d6z\u00e7elik, A.A. (2025). Nusinersen for children with type I spinal muscular atrophy: 4 years\u2019 clinical experience in Turkish cohort. Front. Neurol., 16.","DOI":"10.3389\/fneur.2025.1541507"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13023-025-03603-9","article-title":"Real-world analysis of the efficacy and safety of nusinersen in pediatric patients with spinal muscular atrophy","volume":"20","author":"Li","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1756286418803246","DOI":"10.1177\/1756286418803246","article-title":"Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy","volume":"11","author":"Stolte","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"568197","DOI":"10.2147\/JIR.S568197","article-title":"Rethinking Corticosteroid Therapy in Pediatric Neurology","volume":"19","author":"Lin","year":"2026","journal-title":"J. Inflamm. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/08830738251374539","article-title":"CLN2 Disease: Current Understandings, Challenges, and Future Directions","volume":"41","author":"Shock","year":"2026","journal-title":"J. Child. Neurol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/cts.12925","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration","volume":"14","author":"Kim","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa2307952","article-title":"Intrathecal Gene Therapy for Giant Axonal Neuropathy","volume":"390","author":"Todd","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1474-4422(24)00220-5","article-title":"Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): A multicentre, randomised, double-blind, placebo-controlled phase 3 trial","volume":"23","author":"Zielen","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10545-013-9608-0","article-title":"Blood\u2013brain barrier structure and function and the challenges for CNS drug delivery","volume":"36","author":"Abbott","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2174\/1381612822666151221150733","article-title":"Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier","volume":"22","author":"David","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"32544","DOI":"10.1021\/acsomega.5c00364","article-title":"Overcoming the Blood-Brain Barrier for Drug Delivery to the Brain","volume":"10","author":"Katz","year":"2025","journal-title":"ACS Omega"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Yang, H.-M. (2025). Overcoming the Blood\u2013Brain Barrier: Advanced Strategies in Targeted Drug Delivery for Neurodegenerative Diseases. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17081041"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11910-024-01338-x","article-title":"Strategies to Improve Drug Delivery Across the Blood\u2013Brain Barrier for Glioblastoma","volume":"24","author":"Narsinh","year":"2024","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/s12951-025-03415-w","article-title":"Advances in brain-targeted delivery strategies and natural product-mediated enhancement of blood\u2013brain barrier permeability","volume":"23","author":"Liu","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.addr.2019.07.010","article-title":"Nanocarrier-based systems for targeted and site specific therapeutic delivery","volume":"144","author":"Majumder","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"7291","DOI":"10.2147\/IJN.S146315","article-title":"Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors","volume":"12","author":"Din","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2147\/IJN.S236927","article-title":"Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities","volume":"15","author":"Ruman","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Aderibigbe, B. (2018). In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10020040"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"559","DOI":"10.33263\/BRIAC136.559","article-title":"Drug Discovery in Glioblastoma: Current Status and Future Perspectives","volume":"13","author":"Husain","year":"2023","journal-title":"Biointerface Res. Appl. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1039\/D0TB02957B","article-title":"Recent advances in the design of inorganic and nano-clay particles for the treatment of brain disorders","volume":"9","author":"Persano","year":"2021","journal-title":"J. Mater. Chem. B"},{"key":"ref_102","unstructured":"Tekade, R.K. (2020). Chapter 5\u2014Overview of different carrier systems for advanced drug delivery. Drug Delivery Systems, Academic Press."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s13346-019-00679-2","article-title":"Delivery across the blood-brain barrier: Nanomedicine for glioblastoma multiforme","volume":"10","author":"Jena","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jconrel.2017.12.015","article-title":"Crossing the blood-brain barrier with nanoparticles","volume":"270","author":"Zhou","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Crintea, A., Dutu, A.G., Sovrea, A., Constantin, A.-M., Samasca, G., Masalar, A.L., Ifju, B., Linga, E., Neamti, L., and Tranca, R.A. (2022). Nanocarriers for Drug Delivery: An Overview with Emphasis on Vitamin D and K Transportation. Nanomaterials, 12.","DOI":"10.3390\/nano12081376"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"8241","DOI":"10.1007\/s00210-025-03918-1","article-title":"A comprehensive review on liraglutide and novel nanocarrier-based systems for the effective delivery of liraglutide","volume":"398","author":"Pandey","year":"2025","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e1996","DOI":"10.1002\/wnan.1996","article-title":"Nanomedicine Therapies for Pediatric Diseases","volume":"16","author":"Yang","year":"2024","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Ra\u010di\u0107, A., Gatari\u0107, B., Topi\u0107 Vu\u010denovi\u0107, V., and Stojmenovski, A. (2025). Polysaccharide-Based Drug Delivery Systems in Pediatrics: Addressing Age-Specific Challenges and Therapeutic Applications. Polysaccharides, 6.","DOI":"10.3390\/polysaccharides6040108"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Teleanu, D.M., Chircov, C., Grumezescu, A.M., Volceanov, A., and Teleanu, R.I. (2018). Impact of Nanoparticles on Brain Health: An Up to Date Overview. J. Clin. Med., 7.","DOI":"10.3390\/jcm7120490"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10311-018-00841-1","article-title":"Nanocarriers for drug delivery applications","volume":"17","author":"Chamundeeswari","year":"2019","journal-title":"Environ. Chem. Lett."},{"key":"ref_111","first-page":"261","article-title":"Drug loading methods and kinetic release models using of mesoporous silica nanoparticles as a drug delivery system: A review","volume":"50","author":"Khalbas","year":"2024","journal-title":"S. Afr. J. Chem. Eng."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1801002","DOI":"10.1002\/adhm.201801002","article-title":"Nanocarriers and Their Loading Strategies","volume":"8","author":"Wang","year":"2019","journal-title":"Adv. Healthc. Mater."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v28.i2.10","article-title":"Nanostructured materials in drug and gene delivery: A review of the state of the art","volume":"28","author":"Petkar","year":"2011","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"51","DOI":"10.62347\/QHVI3317","article-title":"Advances in nanotechnology for targeted drug delivery in neurodegenerative diseases","volume":"14","author":"Rafieezadeh","year":"2025","journal-title":"Am. J. Neurodegener. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"18220","DOI":"10.1038\/s41598-020-75253-9","article-title":"Investigating the optimum size of nanoparticles for their delivery into the brain assisted by focused ultrasound-induced blood\u2013brain barrier opening","volume":"10","author":"Ohta","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12951-015-0075-7","article-title":"The effect of nanoparticle size on the probability to cross the blood-brain barrier: An in-vitro endothelial cell model","volume":"13","author":"Shilo","year":"2015","journal-title":"J. Nanobiotechnol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1002\/anie.201403036","article-title":"Engineered Nanoparticles for Drug Delivery in Cancer Therapy","volume":"53","author":"Sun","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e09394","DOI":"10.1016\/j.heliyon.2022.e09394","article-title":"Liposomes: Structure, composition, types, and clinical applications","volume":"8","author":"Nsairat","year":"2022","journal-title":"Heliyon"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1208\/s12248-021-00648-z","article-title":"Understanding Drug Delivery to the Brain Using Liposome-Based Strategies: Studies that Provide Mechanistic Insights Are Essential","volume":"23","author":"Juhairiyah","year":"2021","journal-title":"AAPS J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.2147\/IJN.S117210","article-title":"Getting into the brain: Liposome-based strategies for effective drug delivery across the blood-brain barrier","volume":"11","author":"Vieira","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Fulton, M.D., and Najahi-Missaoui, W. (2023). Liposomes in Cancer Therapy: How Did We Start and Where Are We Now. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076615"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Raju, R., Abuwatfa, W.H., Pitt, W.G., and Husseini, G.A. (2023). Liposomes for the Treatment of Brain Cancer\u2014A Review. Pharmaceuticals, 16.","DOI":"10.3390\/ph16081056"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"114904","DOI":"10.1016\/j.colsurfb.2025.114904","article-title":"Smart liposomal systems for brain cancer: Technological innovations in drug delivery","volume":"255","author":"Zuberi","year":"2025","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"103008","DOI":"10.1016\/j.cis.2023.103008","article-title":"Emerging strategies to fabricate polymeric nanocarriers for enhanced drug delivery across blood-brain barrier: An overview","volume":"320","author":"Song","year":"2023","journal-title":"Adv. Colloid Interface Sci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2003937","DOI":"10.1002\/advs.202003937","article-title":"Development of Polymeric Nanoparticles for Blood-Brain Barrier Transfer-Strategies and Challenges","volume":"8","author":"Zhang","year":"2021","journal-title":"Adv. Sci."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Caraway, C.A., Gaitsch, H., Wicks, E.E., Kalluri, A., Kunadi, N., and Tyler, B.M. (2022). Polymeric Nanoparticles in Brain Cancer Therapy: A Review of Current Approaches. Polymers, 14.","DOI":"10.3390\/polym14142963"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jconrel.2022.07.023","article-title":"Polymeric nanoparticles for drug delivery in glioblastoma: State of the art and future perspectives","volume":"349","author":"Madani","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Su, Y., Sun, B., Gao, X., Dong, X., Fu, L., Zhang, Y., Li, Z., Wang, Y., Jiang, H., and Han, B. (2020). Intranasal Delivery of Targeted Nanoparticles Loaded with miR-132 to Brain for the Treatment of Neurodegenerative Diseases. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.01165"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1080\/10717544.2018.1494226","article-title":"Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting","volume":"25","author":"Chu","year":"2018","journal-title":"Drug Deliv."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cis.2018.06.005","article-title":"PAMAM dendrimer-cell membrane interactions","volume":"257","author":"Fox","year":"2018","journal-title":"Adv. Colloid Interface Sci."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1901001","DOI":"10.1002\/adfm.201901001","article-title":"Branched and Dendritic Polymer Architectures: Functional Nanomaterials for Therapeutic Delivery","volume":"30","author":"Cook","year":"2020","journal-title":"Adv. Funct. Mater."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"105896","DOI":"10.1016\/j.jddst.2024.105896","article-title":"Dendrimers for drug delivery: An overview of its classes, synthesis, and applications","volume":"98","author":"Sarode","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.1021\/acsabm.5c00498","article-title":"Emerging Trends in Designing the Dendrimer-Based Drug Delivery for Antineoplastic Therapies","volume":"8","author":"Firdous","year":"2025","journal-title":"ACS Appl. Bio Mater."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Yan, X., and Chen, Q. (2024). Polyamidoamine Dendrimers: Brain-Targeted Drug Delivery Systems in Glioma Therapy. Polymers, 16.","DOI":"10.3390\/polym16142022"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Kaurav, M., Ruhi, S., Al-Goshae, H.A., Jeppu, A.K., Ramachandran, D., Sahu, R.K., Sarkar, A.K., Khan, J., and Ashif Ikbal, A.M. (2023). Dendrimer: An update on recent developments and future opportunities for the brain tumors diagnosis and treatment. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1159131"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Zhu, Y., Liu, C., and Pang, Z. (2019). Dendrimer-Based Drug Delivery Systems for Brain Targeting. Biomolecules, 9.","DOI":"10.3390\/biom9120790"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.1016\/j.biomaterials.2009.08.049","article-title":"Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer","volume":"30","author":"Ke","year":"2009","journal-title":"Biomaterials"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.biomaterials.2011.11.054","article-title":"Stability and biocompatibility of a library of polyester dendrimers in comparison to polyamidoamine dendrimers","volume":"33","author":"Feliu","year":"2012","journal-title":"Biomaterials"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Carri\u00f3n, M.D., and Posadas, I. (2023). Dendrimers in Neurodegenerative Diseases. Processes, 11.","DOI":"10.3390\/pr11020319"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejpb.2016.12.019","article-title":"Polymeric mixed micelles as nanomedicines: Achievements and perspectives","volume":"113","author":"Cagel","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jconrel.2021.02.031","article-title":"Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions","volume":"332","author":"Ghezzi","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.addr.2020.09.009","article-title":"Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval","volume":"156","author":"Hwang","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1208\/s12249-014-0113-z","article-title":"Polymeric Micelles: Nanocarriers for Cancer-Targeted Drug Delivery","volume":"15","author":"Zhang","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00280-017-3273-1","article-title":"Polymeric micelles as mighty nanocarriers for cancer gene therapy: A review","volume":"79","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"109960","DOI":"10.1016\/j.cbi.2022.109960","article-title":"Advances in designing of polymeric micelles for biomedical application in brain related diseases","volume":"361","author":"Kaur","year":"2022","journal-title":"Chem.-Biol. Interact."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.2147\/IJN.S62263","article-title":"Enhanced brain delivery of lamotrigine with Pluronic(\u00ae) P123-based nanocarrier","volume":"9","author":"Wu","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jconrel.2025.02.018","article-title":"Multidrug micelles and sonopermeation for chemotherapy co-delivery to brain tumors","volume":"380","author":"Dasgupta","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"115481","DOI":"10.1016\/j.addr.2024.115481","article-title":"Drug delivery using gold nanoparticles","volume":"216","author":"Dykman","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"105766","DOI":"10.1016\/j.jddst.2024.105766","article-title":"A glance on gold nanoparticle: An emerging theranostic tool for oncology","volume":"97","author":"Singh","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1021\/nn301282m","article-title":"Size-Dependent Localization and Penetration of Ultrasmall Gold Nanoparticles in Cancer Cells, Multicellular Spheroids, and Tumors in Vivo","volume":"6","author":"Huang","year":"2012","journal-title":"ACS Nano"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1039\/D3TB01976D","article-title":"Harnessing the power of gold: Advancements in anticancer gold complexes and their functionalized nanoparticles","volume":"12","author":"Malik","year":"2024","journal-title":"J. Mater. Chem. B"},{"key":"ref_152","first-page":"11","article-title":"Synthesis of gold nanoparticles and their applications in cancer therapy","volume":"12","author":"Panwar","year":"2024","journal-title":"Biointerface Res. Appl. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41586-019-1564-x","article-title":"Glutamatergic synaptic input to glioma cells drives brain tumour progression","volume":"573","author":"Venkataramani","year":"2019","journal-title":"Nature"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2019.02.025","article-title":"Gold nanoparticles in combinatorial cancer therapy strategies","volume":"387","author":"Beik","year":"2019","journal-title":"Coord. Chem. Rev."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"372","DOI":"10.20892\/j.issn.2095-3941.2020.0524","article-title":"Gold-based nanomaterials for the treatment of brain cancer","volume":"18","author":"Tu","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1038\/s41467-023-40579-1","article-title":"Optical blood-brain-tumor barrier modulation expands therapeutic options for glioblastoma treatment","volume":"14","author":"Cai","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.4103\/1673-5374.313040","article-title":"Advance in the use of gold nanoparticles in the treatment of neurodegenerative diseases: New perspectives","volume":"16","author":"Silveira","year":"2021","journal-title":"Neural Regen. Res."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Puranik, N., Yadav, D., and Song, M. (2023). Advancements in the Application of Nanomedicine in Alzheimer\u2019s Disease: A Therapeutic Perspective. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241814044"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"109486","DOI":"10.1016\/j.inoche.2022.109486","article-title":"Protective effect of the gold nanoparticles green synthesized by Calendula officinalis L. extract on cerebral ischemia stroke-reperfusion injury in rats: A preclinical trial study","volume":"141","author":"Zhao","year":"2022","journal-title":"Inorg. Chem. Commun."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1093\/brain\/awae135","article-title":"Unleashing the potential of mRNA therapeutics for inherited neurological diseases","volume":"147","author":"Monfrini","year":"2024","journal-title":"Brain"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e70110","DOI":"10.1111\/ejn.70110","article-title":"RNA-Based Therapies for Neurodegenerative Diseases Targeting Pathogenic Proteins","volume":"61","author":"Rabbani","year":"2025","journal-title":"Eur. J. Neurosci."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"27","DOI":"10.21926\/rpm.2404027","article-title":"Viral\/Non-Viral Vectors in DNA\/RNA Delivery Technology","volume":"6","author":"Hosseinkhani","year":"2024","journal-title":"Recent. Progress. Mater."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1706910","article-title":"Gene Therapy","volume":"381","author":"High","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd.2016.280","article-title":"Delivery technologies for genome editing","volume":"16","author":"Yin","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jconrel.2021.03.029","article-title":"BBB-crossing adeno-associated virus vector: An excellent gene delivery tool for CNS disease treatment","volume":"333","author":"Chen","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_166","first-page":"Ge01","article-title":"Non viral vectors in gene therapy- an overview","volume":"9","author":"Ramamoorth","year":"2015","journal-title":"J. Clin. Diagn. Res. JCDR"},{"key":"ref_167","first-page":"21","article-title":"Recent advances in gene therapy for neurological disorders: A comprehensive overview","volume":"7","author":"Jindal","year":"2025","journal-title":"Adesh Univ. J. Med. Sci. Res."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Ozair, A., Khan, E., Bhat, V., Faruqi, A., and Nanda, A. (2022). Pediatric Brain Tumors: From Modern Classification System to Current Principles of Management, IntechOpen.","DOI":"10.5772\/intechopen.100442"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00234-019-02172-6","article-title":"Gadolinium retention in gliomas and adjacent normal brain tissue: Association with tumor contrast enhancement and linear\/macrocyclic agents","volume":"61","author":"Kiviniemi","year":"2019","journal-title":"Neuroradiology"},{"key":"ref_171","unstructured":"EMA (2017). EMA\u2019s final opinion confirms restrictions on use of linear gadolinium agents in body scans. Med. Writ., 26, 52."},{"key":"ref_172","unstructured":"FDA (2026, July 20). FDA Drug Safety Communication: FDA Warns that Gadolinium-Based Contrast Agents (GBCAs) are Retained in the Body; Requires New Class Warnings. Available online: https:\/\/www.sentinelinitiative.org\/news-events\/fda-safety-communications-labeling-changes\/fda-warns-gadolinium-based-contrast-agents."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12951-025-03247-8","article-title":"The blood\u2013brain barriers: Novel nanocarriers for central nervous system diseases","volume":"23","author":"Liu","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Pourmasoumi, P., Banihashemian, S.A., Zamani, F., Rasouli-Nia, A., Mehrabani, D., and Karimi-Busheri, F. (2024). Nanoparticle-Based Approaches in the Diagnosis and Treatment of Brain Tumors. J. Clin. Med., 13.","DOI":"10.3390\/jcm13237449"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"371","DOI":"10.54097\/7278ey80","article-title":"Nanotechnology-Based Pharmacological Treatment for Brain Tumors","volume":"125","author":"Xu","year":"2025","journal-title":"Highlights Sci. Eng. Technol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"24205","DOI":"10.1073\/pnas.1911229117","article-title":"Engineered biomimetic nanoparticle for dual targeting of the cancer stem-like cell population in sonic hedgehog medulloblastoma","volume":"117","author":"Kim","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"102115","DOI":"10.1016\/j.nano.2019.102115","article-title":"Nonviral polymeric nanoparticles for gene therapy in pediatric CNS malignancies","volume":"23","author":"Choi","year":"2020","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"65339","DOI":"10.18632\/oncotarget.18689","article-title":"Anti-SSTR2 peptide based targeted delivery of potent PLGA encapsulated 3,3\u2032-diindolylmethane nanoparticles through blood brain barrier prevents glioma progression","volume":"8","author":"Bhowmik","year":"2017","journal-title":"Oncotarget"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"11292","DOI":"10.1038\/s41598-020-68017-y","article-title":"Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: A combinational approach for enhanced delivery of nanoparticles","volume":"10","author":"Norouzi","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"174860","DOI":"10.1016\/j.ejphar.2022.174860","article-title":"Iron oxide nanoparticles loaded with paclitaxel inhibits glioblastoma by enhancing autophagy-dependent ferroptosis pathway","volume":"921","author":"Chen","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Poonaki, E., Nickel, A.-C., Shafiee Ardestani, M., Rademacher, L., Kaul, M., Apartsin, E., Meuth, S.G., Gorji, A., Janiak, C., and Kahlert, U.D. (2022). CD133-Functionalized Gold Nanoparticles as a Carrier Platform for Telaglenastat (CB-839) against Tumor Stem Cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105479"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1021\/acsabm.4c00999","article-title":"Doxorubicin-Loaded Ultrasmall Gold Nanoparticles (1.5 nm) for Brain Tumor Therapy and Assessment of Their Biodistribution","volume":"7","author":"Kruse","year":"2024","journal-title":"ACS Appl. Bio Mater."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7150\/ntno.38954","article-title":"Enhanced blood-brain-barrier penetrability and tumor-targeting efficiency by peptide-functionalized poly(amidoamine) dendrimer for the therapy of gliomas","volume":"3","author":"Liu","year":"2019","journal-title":"Nanotheranostics"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"105439","DOI":"10.1016\/j.ejps.2020.105439","article-title":"Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent","volume":"152","author":"Uram","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_185","unstructured":"World Health Organization (2026, July 25). Epilepsy. Available online: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325293\/9789241515931-eng.pdf?ua=1."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.yebeh.2015.11.009","article-title":"Specific adverse effects of antiepileptic drugs\u2014A true-to-life monotherapy study","volume":"54","author":"Kowski","year":"2016","journal-title":"Epilepsy Behav."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Gernert, M., and Feja, M. (2020). Bypassing the Blood\u2013Brain Barrier: Direct Intracranial Drug Delivery in Epilepsies. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12121134"},{"key":"ref_188","first-page":"17","article-title":"Development of nanoemulsion containing Centella asiatica crude extract as a promising drug delivery system for epilepsy treatment","volume":"13","author":"Thuraisingam","year":"2023","journal-title":"Biointerface Res. Appl. Chem."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.0000000000011839","article-title":"Incidence and Prevalence of Drug-Resistant Epilepsy: A Systematic Review and Meta-analysis","volume":"96","author":"Sultana","year":"2021","journal-title":"Neurology"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40272-021-00448-0","article-title":"Neurocognitive Effects of Antiseizure Medications in Children and Adolescents with Epilepsy","volume":"23","author":"Besag","year":"2021","journal-title":"Pediatr. Drugs"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/WCO.0000000000000803","article-title":"What has been the impact of new drug treatments on epilepsy?","volume":"33","author":"Chen","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"ref_192","first-page":"170","article-title":"Pharmacokinetics and Pharmacodynamics of Levetiracetam in Neonatal Seizures: What We Still Need to Know","volume":"30","author":"Hughes","year":"2025","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1111\/epi.17954","article-title":"Population pharmacokinetics and dosing optimization of perampanel in children with epilepsy: A real-world study","volume":"65","author":"Li","year":"2024","journal-title":"Epilepsia"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1002\/psp4.13191","article-title":"Population pharmacokinetics of valproic acid in children with epilepsy: Implications for dose tailoring when switching from oral syrup to sustained-release tablets","volume":"13","author":"Wang","year":"2024","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jconrel.2020.08.051","article-title":"Conducting polymer hydrogels for electrically responsive drug delivery","volume":"328","author":"Bansal","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/jbm.a.34869","article-title":"A review of integrating electroactive polymers as responsive systems for specialized drug delivery applications","volume":"102","author":"Pillay","year":"2014","journal-title":"J. Biomed. Mater. Res. Part A"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"eabm3381","DOI":"10.1126\/sciadv.abm3381","article-title":"Nanoengineered on-demand drug delivery system improves efficacy of pharmacotherapy for epilepsy","volume":"8","author":"Wu","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12951-020-0580-1","article-title":"Size-isolation of superparamagnetic iron oxide nanoparticles improves MRI, MPI and hyperthermia performance","volume":"18","author":"Dadfar","year":"2020","journal-title":"J. Nanobiotechnol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1021\/acschemneuro.4c00188","article-title":"Heparin-Modified Superparamagnetic Iron Oxide Nanoparticles Suppress Lithium Chloride\/Pilocarpine-Induced Temporal Lobe Epilepsy in Rats through Attenuation of Inflammation and Oxidative Stress","volume":"15","author":"Xu","year":"2024","journal-title":"ACS Chem. Neurosci."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.freeradbiomed.2013.02.002","article-title":"Mitochondrial involvement and oxidative stress in temporal lobe epilepsy","volume":"62","author":"Rowley","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eplepsyres.2009.09.020","article-title":"Mitochondria, oxidative stress, and temporal lobe epilepsy","volume":"88","author":"Waldbaum","year":"2010","journal-title":"Epilepsy Res."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.apsb.2022.09.019","article-title":"ROS-removing nano-medicine for navigating inflammatory microenvironment to enhance anti-epileptic therapy","volume":"13","author":"Zhou","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.actbio.2014.09.018","article-title":"Visible-light-induced synthesis of pH-responsive composite hydrogels for controlled delivery of the anticonvulsant drug pregabalin","volume":"11","author":"Cevik","year":"2015","journal-title":"Acta Biomater."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"056007","DOI":"10.1088\/1478-3975\/12\/5\/056007","article-title":"pH during non-synaptic epileptiform activity-computational simulations","volume":"12","author":"Rodrigues","year":"2015","journal-title":"Phys. Biol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"147345","DOI":"10.1016\/j.brainres.2021.147345","article-title":"Alkaline brain pH shift in rodent lithium-pilocarpine model of epilepsy with chronic seizures","volume":"1758","author":"Lu","year":"2021","journal-title":"Brain Res."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"123203","DOI":"10.1016\/j.ijpharm.2023.123203","article-title":"A stimuli-responsive nanocarrier for diagnosis of seizures and inhibition of glutaminase in epilepsy","volume":"642","author":"Trivedi","year":"2023","journal-title":"Int. J. Pharm."},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Teleanu, R.I., Niculescu, A.-G., Vladacenco, O.A., Roza, E., Perjoc, R.-S., and Teleanu, D.M. (2023). The State of the Art of Pediatric Multiple Sclerosis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098251"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.parkreldis.2020.10.002","article-title":"Parkinsonism in children: Clinical classification and etiological spectrum","volume":"82","author":"Leuzzi","year":"2021","journal-title":"Park. Relat. Disord."},{"key":"ref_209","first-page":"2","article-title":"Clinical approach to children with suspected neurodegenerative disorders","volume":"7","author":"Jan","year":"2002","journal-title":"Neurosci. J."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1474-4422(18)30294-1","article-title":"Biological and clinical manifestations of juvenile Huntington\u2019s disease: A retrospective analysis","volume":"17","author":"Fusilli","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3233\/JHD-231523","article-title":"Clinical Review of Juvenile Huntington\u2019s Disease","volume":"13","author":"Oosterloo","year":"2024","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"34725","DOI":"10.1021\/acsami.9b12319","article-title":"Selenium Nanoparticles as an Efficient Nanomedicine for the Therapy of Huntington\u2019s Disease","volume":"11","author":"Cong","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Teleanu, D.M., Niculescu, A.-G., Lungu, I.I., Radu, C.I., Vlad\u00e2cenco, O., Roza, E., Cost\u0103chescu, B., Grumezescu, A.M., and Teleanu, R.I. (2022). An Overview of Oxidative Stress, Neuroinflammation, and Neurodegenerative Diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23115938"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3109\/10717544.2014.880860","article-title":"Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington\u2019s disease","volume":"22","author":"Bhatt","year":"2015","journal-title":"Drug Deliv."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"2001736","DOI":"10.1002\/adhm.202001736","article-title":"Incorporation of a Biocompatible Nanozyme in Cellular Antioxidant Enzyme Cascade Reverses Huntington\u2019s Like Disorder in Preclinical Model","volume":"10","author":"Adhikari","year":"2021","journal-title":"Adv. Healthc. Mater."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/nnm-2020-0239","article-title":"Epigallocatechin-3-Gallate PEGylated Poly(Lactic-Co-Glycolic) Acid Nanoparticles Mitigate Striatal Pathology and Motor Deficits in 3-Nitropropionic Acid Intoxicated Mice","volume":"16","author":"Cano","year":"2021","journal-title":"Nanomedicine"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.parkreldis.2019.06.025","article-title":"Juvenile parkinsonism: Differential diagnosis, genetics, and treatment","volume":"67","author":"Niemann","year":"2019","journal-title":"Park. Relat. Disord."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00415-020-10291-x","article-title":"Nanoparticles for drug delivery in Parkinson\u2019s disease","volume":"268","author":"Baskin","year":"2021","journal-title":"J. Neurol."},{"key":"ref_219","doi-asserted-by":"crossref","unstructured":"Mogharbel, B.F., Cardoso, M.A., Irioda, A.C., Stricker, P.E., Slompo, R.C., Appel, J.M., de Oliveira, N.B., Perussolo, M.C., Sa\u00e7aki, C.S., and da Rosa, N.N. (2022). Biodegradable Nanoparticles Loaded with Levodopa and Curcumin for Treatment of Parkinson\u2019s Disease. Molecules, 27.","DOI":"10.3390\/molecules27092811"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"120707","DOI":"10.1016\/j.saa.2021.120707","article-title":"Spectroscopic study of L-DOPA and dopamine binding on novel gold nanoparticles towards more efficient drug-delivery system for Parkinson\u2019s disease","volume":"268","author":"Barbir","year":"2022","journal-title":"Spectrochim. Acta Part A Mol. Biomol. Spectrosc."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"17581","DOI":"10.1021\/acsanm.3c02749","article-title":"Selenium Nanoparticles as Potential Drug-Delivery Systems for the Treatment of Parkinson\u2019s Disease","volume":"6","author":"Beus","year":"2023","journal-title":"ACS Appl. Nano Mater."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1093\/brain\/awad242","article-title":"The collective burden of childhood dementia: A scoping review","volume":"146","author":"Elvidge","year":"2023","journal-title":"Brain"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pediatrneurol.2022.11.015","article-title":"Childhood Dementia: A Collective Clinical Approach to Advance Therapeutic Development and Care","volume":"139","author":"Djafar","year":"2023","journal-title":"Pediatr. Neurol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s13023-023-02859-3","article-title":"The psychosocial impact of childhood dementia on children and their parents: A systematic review","volume":"18","author":"Nevin","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13346-025-01863-3","article-title":"Emerging nano-derived therapy for the treatment of dementia: A comprehensive review","volume":"16","author":"Ahmad","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.1038\/s41598-020-63894-9","article-title":"Liposomal drug delivery of Aphanamixis polystachya leaf extracts and its neurobehavioral activity in mice model","volume":"10","author":"Shariare","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/02652048.2020.1756971","article-title":"Memantine nanoemulsion: A new approach to treat Alzheimer\u2019s disease","volume":"37","author":"Kaur","year":"2020","journal-title":"J. Microencapsul."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"P299","DOI":"10.1016\/j.jalz.2013.05.609","article-title":"P1\u2013382: Curcumin-donepezil\u2013loaded nanostructured lipid carriers for intranasal delivery in an Alzheimer\u2019s disease model","volume":"9","author":"Sood","year":"2013","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3109\/1061186X.2012.747529","article-title":"Preparation, characterization, in vivo and biochemical evaluation of brain targeted Piperine solid lipid nanoparticles in an experimentally induced Alzheimer\u2019s disease model","volume":"21","author":"Yusuf","year":"2013","journal-title":"J. Drug Target."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.biomaterials.2013.09.063","article-title":"Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer\u2019s disease mice","volume":"35","author":"Zhang","year":"2014","journal-title":"Biomaterials"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/03639045.2019.1576724","article-title":"Nanostructured lipid carriers engineered for intranasal delivery of teriflunomide in multiple sclerosis: Optimization and in vivo studies","volume":"45","author":"Gadhave","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Chountoulesi, M., and Demetzos, C. (2020). Promising Nanotechnology Approaches in Treatment of Autoimmune Diseases of Central Nervous System. Brain Sci., 10.","DOI":"10.3390\/brainsci10060338"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1038\/s41598-020-58709-w","article-title":"Nanocatalytic activity of clean-surfaced, faceted nanocrystalline gold enhances remyelination in animal models of multiple sclerosis","volume":"10","author":"Robinson","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1021\/acschemneuro.6b00428","article-title":"Enhanced Brain Delivery of Dimethyl Fumarate Employing Tocopherol-Acetate-Based Nanolipidic Carriers: Evidence from Pharmacokinetic, Biodistribution, and Cellular Uptake Studies","volume":"8","author":"Kumar","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"119987","DOI":"10.1016\/j.biomaterials.2020.119987","article-title":"Targeted immunomodulation of inflammatory monocytes across the blood-brain barrier by curcumin-loaded nanoparticles delays the progression of experimental autoimmune encephalomyelitis","volume":"245","author":"Lu","year":"2020","journal-title":"Biomaterials"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.biomaterials.2017.07.029","article-title":"An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors through a dual-sized microparticle system blocks experimental autoimmune encephalomyelitis","volume":"143","author":"Cho","year":"2017","journal-title":"Biomaterials"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"119432","DOI":"10.1016\/j.biomaterials.2019.119432","article-title":"Design of biodegradable nanoparticles to modulate phenotypes of antigen-presenting cells for antigen-specific treatment of autoimmune disease","volume":"222","author":"Saito","year":"2019","journal-title":"Biomaterials"},{"key":"ref_238","doi-asserted-by":"crossref","unstructured":"Osorio-Querejeta, I., Carregal-Romero, S., Ayerdi-Izquierdo, A., M\u00e4ger, I., Nash, L.A., Wood, M., Egimendia, A., Betanzos, M., Alberro, A., and Iparraguirre, L. (2020). MiR-219a-5p Enriched Extracellular Vesicles Induce OPC Differentiation and EAE Improvement More Efficiently Than Liposomes and Polymeric Nanoparticles. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12020186"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.addr.2019.08.008","article-title":"Pharmacokinetics of nanotechnology-based formulations in pediatric populations","volume":"151\u2013152","author":"Yellepeddi","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"105720","DOI":"10.1016\/j.jddst.2024.105720","article-title":"Pediatric drug delivery challenges: Enhancing compliance through age-appropriate formulations and safety measures","volume":"96","author":"Kapoor","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/17425247.4.1.37","article-title":"Paediatric and geriatric drug delivery","volume":"4","author":"Breitkreutz","year":"2007","journal-title":"Expert. Opin. Drug Deliv."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/ajhp\/zxz161","article-title":"Pharmacokinetic considerations in pediatric pharmacotherapy","volume":"76","author":"Lim","year":"2019","journal-title":"Am. J. Health-Syst. Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharm."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"115567","DOI":"10.1016\/j.fct.2025.115567","article-title":"Ferroptosis effects and behavioral changes associated with high accumulation and low elimination percentage of silver in brain following a 28-day nasal instillation of silver nanoparticles in mice","volume":"202","author":"Niu","year":"2025","journal-title":"Food Chem. Toxicol."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3233\/JAD-190204","article-title":"Airborne Magnetite- and Iron-Rich Pollution Nanoparticles: Potential Neurotoxicants and Environmental Risk Factors for Neurodegenerative Disease, Including Alzheimer\u2019s Disease","volume":"71","author":"Maher","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s44222-023-00138-1","article-title":"Controlling the biodistribution and clearance of nanomedicines","volume":"2","author":"Cabral","year":"2024","journal-title":"Nat. Rev. Bioeng."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/toxsci\/kft109","article-title":"Developmental neurotoxicity of engineered nanomaterials: Identifying research needs to support human health risk assessment","volume":"134","author":"Powers","year":"2013","journal-title":"Toxicol. Sci. Off. J. Soc. Toxicol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"e20170195","DOI":"10.1542\/peds.2017-0195","article-title":"Methodological and Ethical Issues in Pediatric Medication Safety Research","volume":"140","author":"Carpenter","year":"2017","journal-title":"Pediatrics"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2014.02.003","article-title":"Paediatric drug development: The impact of evolving regulations","volume":"73","author":"Turner","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_249","doi-asserted-by":"crossref","unstructured":"Rose, K., and St\u00f6tter, H. (2006). ICH E 11: Clinical Investigation of Medicinal Products in the Paediatric Population, Karger. Guide to Paediatric Clinical Research.","DOI":"10.1159\/000097774"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.cmi.2022.08.009","article-title":"The WHO essential medicines list AWaRe book: From a list to a quality improvement system","volume":"28","author":"Sharland","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/archdischild-2019-318676","article-title":"Challenges in clinical trials for children and young people","volume":"106","author":"Lagler","year":"2021","journal-title":"Arch. Dis. Child."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1111\/apa.15254","article-title":"Improved infrastructure and support needed for paediatric clinical trials in Sweden","volume":"109","author":"Mattsson","year":"2020","journal-title":"Acta Paediatr."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1124\/dmd.116.069559","article-title":"Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling","volume":"44","author":"Mehrotra","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/epi.17332","article-title":"Precision medicine for genetic epilepsy on the horizon: Recent advances, present challenges, and suggestions for continued progress","volume":"63","author":"Knowles","year":"2022","journal-title":"Epilepsia"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1002\/epi4.13039","article-title":"Next-generation sequencing in pediatric-onset epilepsies: Analysis with target panels and personalized therapeutic approach","volume":"9","author":"Castellotti","year":"2024","journal-title":"Epilepsia Open"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pediatrneurol.2023.01.004","article-title":"Review of Machine Learning and Artificial Intelligence (ML\/AI) for the Pediatric Neurologist","volume":"141","author":"Gombolay","year":"2023","journal-title":"Pediatr. Neurol."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"16853","DOI":"10.1021\/acsnano.4c02546","article-title":"Nongenetic Precise Neuromodulation and Spatiotemporal Neuroprotection for Epilepsy Therapy via Rationally Designed Multifunctional Nanotransducer","volume":"18","author":"Ren","year":"2024","journal-title":"ACS Nano"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/dmcn.15838","article-title":"Pediatric epilepsy syndromes with associated developmental impairment","volume":"66","author":"Nordli","year":"2024","journal-title":"Dev. Med. Child. Neurol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8727\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:10:15Z","timestamp":1791904215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":258,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["ijms27198727"],"URL":"https:\/\/doi.org\/10.3390\/ijms27198727","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]}}}